Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v3-EN
Language English English
Date Updated 2022-02-23 2022-02-14
Drug Identification Number 02449935 02449935
Brand name XIGDUO XIGDUO
Common or Proper name dapagliflozin and metformin hydrochloride tablets dapagliflozin and metformin hydrochloride tablets
Company Name ASTRAZENECA CANADA INC ASTRAZENECA CANADA INC
Ingredients METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN
Strength(s) 850MG 5MG 850MG 5MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 6 blisters (10 tablets per blister) per carton 6 blisters (10 tablets per blister) per carton
ATC code A10BD A10BD
ATC description BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2022-02-21 2022-02-21
Actual start date
Estimated end date 2022-02-22 Unknown
Actual end date 2022-02-22
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments